Switching from high-efficacy lipid-lowering therapies to simvastatin and low-density lipoprotein cholesterol goal attainment in coronary heart disease/coronary heart disease-equivalent patients

Journal of Clinical Lipidology

Volumn 4, Issue 6, 2010, Pages 491-500

  Tunceli, Kaan ^a   Sajjan, Shiva G ^a   Ramey, Dena R ^a   Neff, David R ^a   Tershakovec, Andrew M ^a   Hu, X Henry ^a   Tomassini, Joanne E ^a   Foody, Joanne M ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cardiovascular diseases; Cholesterol; Goal attainment; Lipoproteins; Statin interventions

Indexed keywords

ATORVASTATIN; EZETIMIBE PLUS SIMVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; SIMVASTATIN;

ACUTE HEART INFARCTION; ADULT; ANALYSIS OF COVARIANCE; ARTICLE; ATHEROSCLEROSIS; BRAIN ISCHEMIA; CARDIAC PATIENT; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; ISCHEMIC HEART DISEASE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; OBSERVATIONAL STUDY; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THERAPY EFFECT;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL, LDL; CORONARY DISEASE; DRUG THERAPY, COMBINATION; FEMALE; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PYRIMIDINES; PYRROLES; RETROSPECTIVE STUDIES; SIMVASTATIN; SULFONAMIDES;

EID: 78649645691     PISSN: 19332874     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacl.2010.10.004     Document Type: Article

References (36)

1. E.S. Ford, U.A. Ajani, and J.B. Croft Explaining the decrease in US deaths from coronary disease, 1980-2000 N Engl J Med 356 2007 2388 2398
2. S. Capewell, D.K. Hayes, and E.S. Ford Life-years gained among US adults from modern treatments and changes in the prevalence of 6 coronary heart disease risk factors between 1980 and 2000 Am J Epidemiol 170 2009 229 236
3. S.M. Grundy, J.I. Cleeman, and C.N. Merz Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines J Am Coll Cardiol 44 2004 720 732
4. S.C. Smith Jr., J. Allen, and S.N. Blair AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute Circulation 113 2006 2363 2372 (Pubitemid 43947981)
5. A.D. Hyre, P. Muntner, A. Menke, P. Raggi, and J. He Trends in ATP-III-defined high blood cholesterol prevalence, awareness, treatment and control among US adults Ann Epidemiol 17 2007 548 555
6. S.S. Nag, G.W. Daniel, and M.F. Bullano LDL-C goal attainment among patients newly diagnosed with coronary heart disease or diabetes in a commercial HMO J Manag Care Pharm 13 2007 652 663
7. D.D. Waters, C. Brotons, and C.W. Chiang Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals Circulation 120 2009 28 34
8. F.Z. Sy, H.M. Choe, and D.M. Kennedy Moving From A to Z: successful implementation of a statin switch program by a large physician group Am J Manag Care 15 2009 233 240
9. D.F. Brzozowski, D. Gayman, and P. Steere Conversion of patients from atorvastatin (Lipitor) 10 mg and 20 mg per day to generic simvastatin 20 mg and 40 mg per day at a staff model health maintenance organization J Manag Care Pharm 15 2009 182
10. D. Atar, R. Carmena, and P. Clemmensen Clinical review: impact of statin substitution policies on patient outcomes Ann Med 41 2009 242 256
11. U.S. Food and Drug Administration. FDA News Release: FDA approves first generic simvastatin June 23, 2006, updated July 5, 2006. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108675.htm. Accessed October 18, 2010.
12. J.J.P. Kastelein, F. Akdim, and E.S.G. Stroes Simvastatin with or without ezetimibe in familial hypercholesterolemia N Engl J Med 358 2008 1431 1443
13. P.P. Toth, C.M. Ballantyne, and M.H. Davidson Changes in prescription patterns for ezetimibe/simvastatin, ezetimibe + statin and statin therapies and expected effects on LDL-C reduction J Clin Lipid 4 2010 219 220
14. IMS Health. IMS LRx Longitudinal Database. Custom Study thru 2010.
15. Cholesterol Treatment Trialists (CTT) Collaborators Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278
16. J.G. Robinson, B. Smith, N. Maheshwari, and H. Schrott Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis J Am Coll Cardiol 46 2005 1855 1862
17. U.S. Department of Health and Human Services Healthy People 2010 2nd ed. 2000 U.S. Government Printing Office Washington
18. P.M. Kearney, L. Blackwell, and R. Collins Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis Lancet 371 2008 117 125
19. C.R. Harley, S.K. Gandhi, H. Heien, K. McDonough, and S.P. Nelson Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care Exp Opin Pharmacol 9 2008 669 676
20. H.D. Aronow, G. Hess, J. Hill, A. Kuznik, and L.Z. Liu Switching from atorvastatin to simvastatin in patients at high cardiovascular risk: effects on low-density lipoprotein cholesterol Am J Ther 17 2010 167 175
21. G. Hess, K.N. Sanders, J. Hill, and L.Z. Liu Therapeutic dose assessment of patient switching from atorvastatin to simvastatin Am J Manag Care 13 Suppl 3 2007 S80 S85
22. D.A. Rublee, and J.P. Burke LDL-C goal attainment in patients who remain on atorvastatin or switch to equivalent or non-equivalent doses of simvastatin: a retrospective matched cohort study in clinical practice Postgrad Med 122 2010 16 24
23. National Committee for Quality Assurance The State of Health Care Quality 2008 2008 National Committee for Quality Assurance Washington, DC
24. U.S. Food and Drug Administration. FDA Drug Safety Communication: Ongoing safety review of high-dose Zocor (simvastatin) and increased risk of muscle injury. March 19, 2010. Available at: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm204882.htm. Accessed October 18, 2010.
25. AstraZeneca Crestor (rosuvastatin calcium) tablets [package insert] 2010 AstraZeneca Wilmington, DE
26. Merck/Schering-Plough Pharmaceuticals Vytorin [product insert] 2010 Merck/Schering-Plough Pharmaceuticals N. Wales, PA
27. Merck/Schering-Plough Pharmaceuticals Zetia [product insert] 2009 Merck/Schering-Plough Pharmaceuticals N. Wales, PA
28. Pfizer Lipitor (atorvastatin calcium) tablets [package insert] 2009 Pfizer New York, NY
29. V.J. Willey, J.A. Reinhold, K.H. Willey, B.L. Kelly, and M.J. Cziraky Clinical and economic outcomes in patients switched to simvastatin in a community-based family medicine practice Int J Clin Practice 64 2010 1235 1238
30. J.A. Usher-Smith, T. Ramsbottom, H. Pearmain, and M. Kirby Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a Primary Care setting Int J Clin Pract 61 2007 15 23
31. B. Phillips, C. Roberts, A.E. Rudolph, S. Morant, F. Aziz, and C. O'Regan Switching statins: the impact on patient outcomes B J Cardiol 14 2007 280 285
32. M. Thomas, and J. Mann Increased thrombotic vascular events after change of statin Lancet 352 1998 1830 1831
33. R. Butler, and J. Wainwright Cholesterol lowering in patients with CHD and metabolic syndrome Lancet 369 2007 27
34. R.J. Willke, S. Zhou, and R.A. Vogel Differences in cardiovascular event rates between atorvastatin and simvastatin among new users: managed-care experience Curr Med Res Opin 24 2008 2873 2882
35. A.L. Gould, G.M. Davies, E. Alemao, D.D. Yin, and J.R. Cook Cholesterol reduction yields clinical benefits: Meta-analysis including recent trials Clin Ther 29 2007 778 794
36. J.G. Robinson, M.H. Davidson, and A. Shah Efficacy and safety of ezetimibe and ezetimibe+statin therapy in patients aged <65, 65-74, and 75 years and older Aging Health 3 2007 691 705